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Purpose. It is well known that chemotherapy regimens may have a negative eﬀect on ovarian reserve, leading to amenorrhea or
premature ovarian failure. There are little data regarding the eﬀects of leukemia chemotherapy on ovarian reserve, speciﬁcally
in women who received the chemotherapy as adults and are having regular menstrual periods. Our primary objective was to
determine if premenopausal women with a history of chemotherapy for leukemia, without subsequent stem cell transplantation,
havedecreasedovarianreserve.Materials and Methods.Wemeasuredovarianreserveinﬁvewomenwhohadbeentreatedforacute
lymphocytic leukemia (ALL) or acute myeloid leukemia (AML) and compared them to age-matched control women without a
history of chemotherapy. Results. There appeared to be a trend towards lower antimullerian hormone and antral follicle counts
andhigher follicle-stimulatinghormonelevels intheleukemiagroup.Conclusion.Ourresultsindicate that chemotherapy forAML
or ALL without stem cell transplantation may compromise ovarian reserve. Although our results should be conﬁrmed by a larger
study, oncologists, infertility specialists, and patients should be aware of the potential risks to ovarian function and should be
counseled on options for fertility preservation.
1.Introduction
Approximately 20,000 reproductive-aged American women
carry a diagnosis of leukemia [1]. For women less than 45
years old at the time of diagnosis, the 5-year survival rate
is approximately 50% and 40% for women with AML and
ALL.Cancerpatientsarenotonlyfocusedonsurvival,buton
quality of life and long-term plans, such as family building.
Health care providers have recognized the importance of
fertilitytocancerpatientsandtheimpactofcancertreatment
on fertility. The American Society of Clinical Oncology
recommends that fertility preservation be discussed at the
time of diagnosis [2, 3].
Chemotherapeutics have a range of gonadotoxic eﬀects.
In general, methotrexate, ﬂuorouracil, vincristine, bleomy-
cin, and dactinomycin are associated with a low or no risk
of amenorrhea, which is used as a surrogate marker for
infertility, while alkylating agents are more likely to cause
ovarian damage and amenorrhea [2]. Alkylating agents, like
cyclophosphamide, may lead to early menopause by dam-
aging primordial follicles [4, 5]. Anthracyclines, used for
induction remission and postremission chemotherapy in2 ISRN Oncology
young adults with acute myeloid leukemia (AML) and acute
lymphocytic leukemia (ALL), also likely lead to ovarian
damage [6, 7].
Ovarian reserve refers to the number of primordial ovar-
ian follicles in the ovaries and is related to fertility potential
[8]. Infertility is more likely in women with reduced ovarian
reserve [9]. Ovarian function can be monitored clinically,
by the presence of regular menstrual periods. However, a
menstrual cycle is not synonymous with normal fertility or
o vari anr e s e rv e .I nfact ,w o m e nwh ocy c l er eg u l arl ym a yh a v e
diminished ovarian reserve [10]. Thus, biochemical tests are
oftenemployedtoassessovarianreserve.Ovarianreservecan
be measured by menstrual cycle day 3 follicle stimulating
hormone (FSH) and estradiol, inhibin B (INB), ovarian
antral follicle count (AFC), or antimullerian hormone
(AMH).
In the current study, we examined ovarian reserve in
women in ﬁrst complete remission of leukemia who under-
went treatment with standard chemotherapy, but who did
not require stem cell transplantation. We hypothesized that
premenopausal women with a history of chemotherapy for
leukemia, even if stem cell transplantation is not performed
and menstrual cycles are regular, have decreased ovarian
reserve.
2.MaterialsandMethods
We conducted a cross-sectional study of premenopausal
women, aged 18–45, with a history of chemotherapy treat-
ment for ALL, AML, or acute promyelocytic leukemia
(APML). The Institutional Review Board of Dana Farber/
Harvard Cancer Center approved this study. All participants
signed informed consent and were compensated for partici-
pation.
There was a minimum of at least 6 months since
the completion of chemotherapy. Participants could be in
remission or on maintenance therapy. A healthy aged-
matched comparison group from the same catchment area
wasrecruited.Womenwithinfertilityandthosewithmedical
conditions that may compromise fertility or aﬀect ovarian
reserve markers such as a history of hysterectomy or oo-
phorectomy were excluded. Women using hormonal therapy
were excluded or required to stop it for one month prior to
study participation.
Tests for ovarian reserve included serum AMH, estradiol,
FSH, INB, AFC and ovarian volume. All participants were
tested once on cycle days 2–4 of their menstrual cycle. The
primary author performed all transvaginal ultrasounds to
calculate AFC, and ovarian volumes. The AFC included
all follicles in both ovaries 2–10mm in diameter. Ovarian
volume was calculated by multiplying the longest dimension
of the ovary (in cm) by the two orthogonal dimensions
by a factor of 0.523: ovarian volume = length × width ×
thickness × 0.523 [11].
We stored serum samples at −70◦C. All samples were
batched and concurrently analyzed. Serum estradiol was
measured by the Access chemiluminescence immunoassay
(Bechman Coulter, Fullerton, CA); coeﬃcient of varia-
tion (CV) was between 21–50% for levels of estradiol
120–50pg/mL. Serum FSH was measured by the Access
chemiluminescenceimmunoassay(BechmanCoulter,Fuller-
ton,CA),CV<10%.SerumAMHwasmeasuredbyenzyme-
linked immunosorbent assay (ELISA) (DSL Laboratories,
Fremont, CA), intra-assay CV <5% and interassay CV 6%.
Serum INB was measured by ELISA (DSL Labs, Fremont,
CA), intra-assay CV <5% and interassay CV 7%.
The power calculation was based on a 2-sample inde-
pendent t-test to compare the mean AMH level between the
leukemia group and the comparison group. In a previous
study, the response within each subject group was normally
distributedwithstandarddeviation0.9ng/mL[10,12].Ifthe
true diﬀerence in the cancer participants and comparison
means is 1.0ng/mL, we needed to study 14 women with
leukemia and 14 comparison women to be able to reject
the null hypothesis that the population means of the cancer
and comparison groups are equal with probability (power)
0.8. Assuming 20% loss to followup, we tried to recruit 17
leukemia patients and 17 comparison participants. However,
we were only able to recruit 5 participants. Since the relapse
rates are high and overall survival without a transplant is low
in AML and ALL, there were a limited number of eligible
patients. Our participants were aged matched (±1y e a r )t o
ensure equal age distribution in both groups. We matched
the comparison participants to the leukemia participants
1:1.
We compared the continuous variables (AMH, estradiol,
FSH, AFC, INB, and ovarian volume) between the leukemia
subjectsandthecomparisonsubjectsusingWilcoxonsigned-
ranktestsformatchedpairs.Inaddition,weusedMcNemar’s
test based on the exact binomial distribution to look at the
rate of decreased ovarian reserve markers within each group.
We deﬁned decreased ovarian reserve as menstrual cycle day
3F S Ho f≥10.0mIU/mL, estradiol of ≥80pg/mL, INB of
<25pg/mL, AMH <0.9ng/mL, or AFC of <5. The type I
error probability for all two-sided statistical tests was 0.05.
Analyses were performed using Statistical Analysis Software
(SAS) version 9.1 (SAS Institute, Inc., Cary, NC).
3. Results
Five women with leukemia and ﬁve comparison women
participated. At the time of study involvement, all of the
participants had completed therapy; none were on mainte-
nance therapy. Table 1 represents their treatment history and
Table 2 describes menstrual change in regards to chemother-
apy. None of the participants had a history of pregnancy
priortoorafterchemotherapy;however,nonehadattempted
conception. The average age of menarche was 11.6 ± 0.6
years. Sixty percent of participants used only GnRH agonist
menstrual suppression during chemotherapy and the other
2 participants used combined oral contraceptive pills (COC)
and a GnRH agonist. The mean duration of GnRH agonist
therapy was 16 months (range 3–31 months).
Table 3 includes markers of ovarian reserve. There were
no signiﬁcant diﬀerences in any of the markers of ovarian
reserve between the leukemia and the comparison group.
However, there was a trend toward a lower AMH and AFC
and higher FSH in the leukemia group. Three of the womenISRN Oncology 3
Table 1: Chemotherapy regimens.
Subject Diagnosis Age at study
participation
Age at
diagnosis
Duration of
chemotherapy (months) Chemotherapy regimen
Induction: prednisone, vincristine, doxorubicin, MTX,
L-asparaginase
CNS therapy: cranial radiation, vincristine, doxorubicin,
6-MP, IT MTX/ARA-C/hydrocortisone
1 ALL 39 35 14 Intensiﬁcation therapy cycle 1–7: vincristine,
dexamethasone, 6-MP, doxorubicin, asparaginase
Intensiﬁcation therapy cycle 8: vincristine,
dexamethasone, 6-mercaptopurine, MTX
Maintenance: vincristine, MTX, prednisone, 6-MP
2 AML 33 29 3 7+ 3 induction
HiDAC consolidation cycle 1 and 2
Induction: ATRA + idarubicin
3A P M L 3 3 2 9 1 9 Consolidation cycle 1: ATRA, idarubicin
Consolidation cycle 2: ATRA, mitoxantrone
Consolidation cycle 3: ATRA, idarubucin
Maintenance: ATRA, 6-MP, MTX × 12 months
Induction: 7+ 4 induction with ATRA
4A P M L 2 7 2 5 7 Consolidation 1 and 2: arsenic trioxide
Consolidation cycle 3 and 4: daunorubicin and ATRA
Cycle 4: ATRA, MTX, 6MP × 12 months
Prophase and induction: methylprednisolone, IT ARA-C,
prednisone, vincristine, doxorubicin, MTX,
PEG-asparaginase, IT MTX/ARA-C/hydrocortisone, IT
MTX/hydrocortisone
Consolidation IA: vincristine, doxorubicin, IT
MTX/hydrocortisone, high-dose MTX, 6-MP
Consolidation IB: cyclophosphamide, IT
MTX/hydrocortisone, ARA-C, 6-MP
5 ALL 25 21 21 Consolidation IC: HiDAC, etoposide, dexamethasone,
PEG-asparaginase
PEG-asparaginase during consolidation IC and continued
through CNS phase and consolidation II for 15 doses
CNS therapy: vincristine, doxorubicin, 6-MP,
dexamethasone, PEG-asparaginase, IT
MTX/ARA-C/hydrocortisone, cranial radiation
Consolidation II, Cycle 1–8: doxorubicin, dexamethasone,
vincristine, 6-MP, PEG-asparaginase, MTX
IT MTX/ ARA-C/hydrocortisone
Continuation therapy, Cycle 1–20: dexamethasone,
vincristine, 6-MP, MTX
ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, APML: acute promyelocytic leukemia, MTX: methotrexate, ARA-C: cytarabine, HiDAC:
high-dose cytarabine, 6-MP: 6-mercaptopurine, and ARTA: all-trans retinoic acid.
in the leukemia group had abnormal AMH and FSH levels,
compared to one in the comparison group. The 3 women
with subnormal AMH levels had duration of treatment >12
months and one of these women was 35 years old at the time
of treatment.
4. Discussion
In this age-matched study of ovarian reserve in preme-
nopausal women who underwent chemotherapy without
transplantation for acute leukemia, there were no statistically
signiﬁcant diﬀerences in ovarian reserve markers between
the groups. However, there appeared to be a trend towards
decreased ovarian reserve in leukemia survivors. Survivors
may be falsely reassured that their regular menses represents
normal ovarian reserve and may not seek consultation for
fertility preservation until near ovarian failure. Our ﬁndings
suggestthatpatientstreatedwithchemotherapyforleukemia
who continue to menstruate should be tested for decreased
ovarian reserve after treatment. Furthermore, they should
not delay consultation with an infertility specialist if they
have diﬃculty conceiving.4 ISRN Oncology
Table 2: Timing of chemotherapy, hormonal treatments, and menstrual change.
Subject Age
Time since
chemotherapy
(years)
Time between
menarche and
chemotherapy
(years)
Menstrual
change during
chemotherapy
Time to return
of menses
(months)
Duration of
COC (months)
Duration of
GnRH agonist
(months)
Menstrual
change after
chemotherapy
1 39 3.7 23 Stopped 9–12 0 Unknown Lighter
2 33 4.0 18 Stopped <10 . 53
Restarted and
returned to
normal
3 33 2.4 18 Stopped >12 0 31
Restarted and
returned to
normal
4 27 0.5 14 More frequent <1 24 6 Lighter
5 25 1.8 12 Stopped 6–9 0 24 Lighter
COC: combined oral contraception. GnRH agonist: gonadotropin releasing hormone agonist.
Table 3: Ovarian reserve markers in the leukemia and comparison groups.
Group Subject Age
(years)
Follicle
stimulating
hormone
(mIU/mL)
Estradiol
(pg/mL) AMH (ng/mL) Inhibin B
(pg/mL)
Antral follicle
count
Ovarian volume
(cm3)
L 1 39 15.7 20.2 0.05 45.3 7 1.8
C 1 38 71.2 75.6 <0.02 29.3 6 7.3
L 2 33 6.2 96.5 1.87 18.9 13 4.7
C 2 34 5.4 32.2 3.5 68.6 28 11.8
L 3 33 15.6 24.6 <0.02 116 3 9.6
C 3 34 5.0 27.6 4.4 57.9 19 3.6
L 4 27 10.0 28.8 1.86 36.5 12 1.8
C 4 27 9.1 33.6 2.8 84.8 17 7.6
L 5 25 7.7 37.2 0.69 23.9 14 4.1
C 5 26 8.8 44.6 3.14 114 20 7.3
L Median
(Range)
10.0
(6.2–15.7)
28.8
(20.2–96.5)
0.69
(0.02–1.87)
36.5
(18.9–116)
12
(3–14)
4.1
(1.8–9.6)
C Median
(range)
8.8
(5.0–71.2)
33.6
(32.2–75.6)
3.5
(0.02–4.4)
68.6
(29.3–114)
19
(6–28)
7.3
(3.6–11.8)
L: leukemia group; C: comparison group. Matched subjects have the same number. Ovarian volume is the average volume of the right and left ovary.
In the oncology literature, “ovarian failure” is described
in a number of ways: treatment-induced amenorrhea,
menopausal levels of FSH or estradiol, menopausal symp-
toms, or infertility. In our study, women with longer treat-
ment durations had lower ovarian reserve. Similarly inﬂu-
enced by their age at treatment and the stage of cancer,
approximately50–80percentofwomenthatreceivedchemo-
therapyforHodgkin’slymphomahadsecondaryamenorrhea
[13, 14]. However, 75 percent of women with a history
of treatment for Hodgkin’s lymphoma achieved pregnancy
without assisted reproductive technologies [15]. Of note, the
mean age of diagnosis was 23 years old, and those treated
after the age of 30 were less likely to achieve posttreatment
pregnancy. Aisner et al. found a similar pregnancy rate in
their female Hodgkin’s survivors, and as the length of time
after therapy increased so did the probability of pregnancy
[16]. Unfortunately, similar data in leukemia survivors do
not currently exist outside this paper. Given the overwhelm-
ing evidence of diminished ovarian function following treat-
ment for other hematologic malignancies, a reproductive-
agedwomanwithanewhematologiccancerdiagnosisshould
be aware of her potential options to retain her fertility and
ovarian function [17]. Such options include oocyte, ovarian
tissue, or embryo cryopreservation, which are selected based
on the patient’s clinical and social situation.
There are limited data on pregnancy outcomes and
infertility incidence after cancer treatment. However, there
are a small number of epidemiologic studies examining
parenthood after a history of cancer treatment. Compared to
the Norwegian general population of women, of whom 79%
become parents, signiﬁcantly fewer women (66%) with a
history of cancer become parents. Moreover, the pregnancies
of women with a history of cancer were complicated by low
birth weight and premature deliveries [18]. Of note, 31%ISRN Oncology 5
of these women had malignant melanoma (none speciﬁed
as having leukemia). These ﬁndings are similar to a Finnish
study that measured probability of parenthood in women
diagnosed with cancer between 20–34 years old compared
to their siblings [19]. The probability of parenthood in
survivors compared to siblings was 38% versus 73%. Only
a small proportion (3.6%) of those studied had leukemia.
There are more data on pregnancy outcomes of women
diagnosed with leukemia as children than women diagnosed
as adults, which reﬂects the improved survival rate in this
age group compared to adults with acute leukemia. Among
participants in the Childhood Cancer Survivor Study, the
chance of live birth was signiﬁcantly less (RR 0.52, 95% CI
0.36–0.76) for women treated with chemotherapy compared
to their healthy siblings [20] .F o rw o m e nw h od i dd e l i v e r ,
oﬀspring were more likely to be of low birth weight.
Signorelloetal.alsofoundthatsurvivorswerenearlytwiceas
likely to have premature deliveries [21]. The aforementioned
studies describe pregnancy outcomes and parenthood for
many types of cancer, but leukemia patients are not well
represented. Leukemia survivors are a large part of the
Childhood Cancer Survivor Study participants, but these
females were diagnosed when younger than age 22. Thus, the
oncologyandfertilityliteraturelacksinformationonovarian
reserve after adult diagnosis and treatment of leukemia.
Another aim of our study was to determine which ovar-
ian reserve markers performed best in this population. The
optimal ovarian reserve testing may be diﬀerent for cancer
survivors than for women with other infertility etiologies. In
a study of Childhood Cancer Survivors, women with normal
FSH levels (<10mUI/mL) and normal menstrual cycles were
f o u n dt oh a v eal o w e rA F Ca n do v a r i a nv o l u m e sc o m p a r e d
to age-matched controls [22]. Similarly, AMH levels were
lower in women treated as children with chemotherapy for
Hodgkin’s lymphoma, even in women with normal FSH
and INB levels. Thus, AMH appears to be an earlier and
more sensitive marker of ovarian reserve in women with
a history of chemotherapy [10]. Our study also showed a
trend towards low AMH and AFC, with normal FSH in the
leukemia group.
Unlike FSH or estradiol, the interpretation of AMH is
not menstrual cycle-day dependent [23]. During and after
treatment, she may be amenorrheic from the chemotherapy
or GnRH agonist use, and her cycle day unknown. Also, she
often cannot postpone urgent chemotherapy for a menstrual
cycle day 3 FSH evaluation. Thus, the ability to evaluate
ovarian reserve regardless of menstrual status suggests that
AMH is an excellent ovarian reserve marker for the cancer
population.
Current options for fertility preservation in cancer
patients receiving chemotherapy include embryo cryopreser-
vation after in vitro fertilization (IVF), oocyte cryopreserva-
tion, and ovarian suppression with gonadotropin releasing
hormone (GnRH) agonists or antagonists [2]. In addition,
ovarian tissue cryopreservation, currently experimental, may
be considered more in the future [24]. Aside from IVF
potentially being cost or time prohibitive for young women,
especially those needing urgent chemotherapy for acute
leukemia, IVF and embryo cryopreservation may not be
desirable to single women, as they would need donor
sperm.Theymayconsideroocytecryopreservation;however,
this is still thought to be experimental, requires ovarian
stimulation, and may not be feasible in the acute leukemia
population because of the need to delay chemotherapy [25].
Many providers oﬀer women GnRH agonists, as it may be
covered by insurance and can be given without delaying
chemotherapy. However, in 2006, the American Society of
Clinical Oncology stated there was “insuﬃcient evidence
regarding the safety and eﬀectiveness of GnRH analogs
and other means of ovarian suppression on female fertility
preservation [2].”
The primary limitation of this study was its size and we
encourage providers to consider this when interpreting the
results. Although our participants were from an academic
center in a large city, we still had diﬃculty with recruitment.
A multicenter study is required to achieve recruitment for an
adequately powered study. Low numbers of eligible patients
may reﬂect that very few women with leukemia are able to
be cured with chemotherapy alone. For those who have a
goodprognosis,andmaynotneedtransplantation,ourstudy
suggests that there may be long-term implications regarding
fertility. Due to the lack of data in the ﬁeld regarding
the impact of leukemia treatment on menstrual cycles and
infertility, we feel thatour study is a worthwhilecontribution
and may assist with patient counseling. We believe that
women treated with chemotherapy for leukemia should
be counseled that their ovarian reserve may be negatively
impacted.
In conclusion, we determined that premenopausal
women who have received chemotherapy as adults for leuke-
mia may have compromised ovarian reserve, even in the
setting of regular menses. Oncologists, infertility specialists,
and patients should consider our results when discussing the
impact of chemotherapy and fertility preservation. Further,
women and providers may be able to have a more realistic
conversation about the options for fertility preservation.
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